Automated Breast Radiation Therapy Using an MR-Guided Process
This trial is active, not recruiting.
|Treatment||imrt + ct + mr scan|
|Sponsor||University Health Network, Toronto|
|Collaborator||Princess Margaret Hospital, Canada|
|Start date||March 2013|
|End date||January 2017|
|Trial size||160 participants|
|Trial identifier||NCT01999062, UHN REB 12-5181-CE|
In the proposed research study, we are investigating the feasibility of integrating automated planning tools to MR images acquired using a novel MR-guided linac, for on-line adaptive radiation treatment. However, these on-line automation tools require further technical refinement and clinical validation. The goal of this research proposal is to develop an on-line MR-guided radiation therapy process for adapting breast IMRT treatment. Such an approach will provide early stage breast cancer patients timely access to high-quality adaptive treatments without exposure to additional ionizing radiation.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
Time between planning of Radiation treatment and the start of radiotherapy
time frame: 3 years
The effect of breathing on the position of the heart and lung in treatment plans
time frame: 3 years
Female participants at least 18 years old.
- Patients who will receive standard two-field tangential whole breast radiation therapy with dose prescription of 4240 cGy in 16 fractions, 5000 cGy in 25 fractions or 4000 cGy in 16 fractions.
- Female patients with any stage of breast cancer.
- Patients with prior treatment such as surgery or chemotherapy for any type of cancer.
- Able to provide a written informed consent.
- ≥ 18 years of age.
- Patients who will not receive 4240 cGy in 16 fractions, 5000 cGy in 25 fractions, or 4000 cGy in 16 fractions
- Patients who received partial breast radiation and not the standard dose.
- Patients who are unable to provide informed consent.
- < 18 years of age.
|Official title||Automated Breast Radiation Therapy Using an MR-Guided Process|
|Principal investigator||Robert Dinniwell, M.D.|
Call for more information